Privo Technologies

Privo Technologies, Inc. is developing a novel, nanotechnology-based drug delivery platform capable of local systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoid stomach acids, can significantly reduce toxic side effects of drugs, and allows for higher dosing where the drugs can be most effective - all of which improve patient outcomes and compliance. 

This company is a spinout of the 2012 project Targeting Oral Cancer.

In October 2019, Privo announced a $2 million FDA grant award for a clinical study of a product for patients with oral cancer.